Related Experiment Video
Updated: Jul 5, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
[Efficiency of bortezomib and dexamethasone in relapsed multiple myeloma treatment: retrospective study in
P Khosravi Shahi1, P Sabin Domínguez, S Encinas García
1Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid. drkhosravi@hotmail.com
Introduction:
Multiple myeloma (MM) is a plasm-cell neoplasm, that is characterized by a monoclonal protein in the serum or urine. Bortezomib is an efficacy drug for the second line treatment of MM.
Patients And Method:
We conducted a retrospective study of 21 consecutive cases with refractory MM treated with bortezomib and dexamethasone as second line therapy, with the objective of analyzing the overall response rate (primary end point), the progression-free survival (PFS), the overall survival (OS), the duration of response (DR) and toxicity profile (second end points).
Results:
In our study we found an overall response rate of 70%. With a median follow-up of 15 months, we had a median PFS of 12 months (95% CI: 2-21 months), with a median OS of 17 months (95% CI: 2-32 months), and a median DR of 9 months (95% CI: 5-13 months). Fourty-seven percent of patients had neuropathy, the 33% thrombocytopenia, 13.33% anemia and 26.66% diarrhea.
Conclusions:
The combination of bortezomib and dexamethasone is an effective and safe treatment in second line of refractory MM, with a manageable toxicity.
Insights
The combination of bortezomib and dexamethasone shows a 70% overall response rate in refractory multiple myeloma (MM) patients. This treatment is effective and safe for second-line therapy, with manageable side effects.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Context:
- Multiple myeloma (MM) is a plasma cell neoplasm.
- Bortezomib is an effective drug for second-line MM treatment.
Purpose:
- To evaluate the efficacy and safety of bortezomib and dexamethasone in refractory MM.
- Analyze overall response rate, progression-free survival (PFS), overall survival (OS), duration of response (DR), and toxicity.
Summary:
- Retrospective study of 21 refractory MM patients treated with bortezomib and dexamethasone.
- Achieved a 70% overall response rate, with median PFS of 12 months and median OS of 17 months.
- Common toxicities included neuropathy (47%), thrombocytopenia (33%), and diarrhea (26.7%).
Impact:
- Bortezomib and dexamethasone combination is an effective and safe second-line treatment for refractory MM.
- Demonstrates a manageable toxicity profile, supporting its clinical utility.